Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL M. Alexander Otto, PA, MMSc May 30, 2026

https://www.medscape.com/viewarticle/tafasitamab-combo-boosts-r-chop-frontline-dlbcl-2026a1000i14 Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma and high-grade B-cell lymphoma, according to the phase 3 frontMIND trial. https://www.medscape.com/c25/p14/american-society-clinical-oncology-asco-2026-2026a1000c7g